Pharma Mar : Q3 2021 numbers below expectations. Cutting estimates to reflect pipeline delays
>Results below estimates due to weaker Yondelis sales and lower-than- expected Zepzelca royalties - Total revenues declined 13% y-o-y in Q3 2021 (vs +20% in Q2 2021) to € 27m, 10% below our expectations, with Biopharma sales receding slightly (-1% y-o-y in Q3 2021 compared with +22% in the previous quarter) due to stagnant sales of Yondelis (-13% y-oy), hit by pricing pressure in some southern European countries and a 79% drop in the sales of the diagnostic division d...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.